EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION

Michael Chiorean  ¹     Severine Vermeire  ²     Julian Panés  ³     Laurent Peyrin-Biroulet  ⁴     Jinkun Zhang  ⁵     Bruce E. Sands  ⁶     Chris Cabell  ⁶     Snehal U. Naik  ⁶     William Sandborn  ^7    
1 Virginia Mason Medical Center, Seattle, United States
² University Hospital Leuven, Leuven, Belgium
³ Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
⁴ INSERM U 954, Lorraine University, Vandoeuvre-lès-Nancy, France
⁵ Arena Pharmaceuticals, San Diego, United States
⁶ Icahn School of Medicine at Mount Sinai, New York, United States
⁷ University of California San Diego, La Jolla, United States

Session
IBD Clinical III

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)